Trials / Completed
CompletedNCT01936896
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 21 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure. In this study we plan to determine whether treatment with plasma derived alpha-1 antitrypsin will quench the inflammatory response in patients with acute ST-segment elevation myocardial infarction (STEMI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alpha 1-Antitrypsin |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-06-01
- Completion
- 2014-07-01
- First posted
- 2013-09-06
- Last updated
- 2016-02-12
- Results posted
- 2016-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01936896. Inclusion in this directory is not an endorsement.